the Image

Clinical Trial Details

If you are a patient or a caregiver and would like to learn more our cancer clinical trials call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials) or email cancerclinicaltrials@bsd.uchicago.edu .

Share this:
Brief Title A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer
Official Title Atezolizumab in Combination With Gemcitabine and Cisplatin As First-Line Treatment in Metastatic Urothelial Cancer: A Multicenter Randomized Phase II Study of Two Alternative Dosing Schedules
Principal Investigator O'Donnell, Peter
Brief Summary The purpose of this study is to compare any good and bad effects the study drug atezolizumab has on the cancer when combined with the standard chemotherapy drugs gemcitabine and cisplatin (or GC) in two different dosing schedules: chemotherapy (GC) before atezolizumab vs. GC after atezolizumab.
Gender All
Ages 18 Years
Enrollment 31
Accepts Healthy Volunteers No
Lead Sponsor Memorial Sloan Kettering Cancer CenterOther
Collaborator Ohio State UniversityOther
Study Design
Study Phase Phase 2
Study Type Interventional
Contact Name Jonathan Rosenberg, MD
Contact Phone 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials)
Condition Urothelial Carcinoma
Detail for Health Professional (on clinicaltrials.gov)
More clinical trials by this PI